Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of SQ house dust mite sublingual immunotherapy tablet in Thai patients with HDM respiratory allergy
TCTR20200515009Phase 4Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of House dust mite allergen extract in allergic rhinitis (AR), allergic asthma, sponsored by Abbott Laboratories. Started Aug 2020; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)allergic asthma
Beyond the preview
Go deeper on TCTR20200515009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200515009.